Adlai Nortye Ltd.
About Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $640.8M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $640.8M
- Dividend yield
- 9.78%
- Shares outstanding
- 62.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 29, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 38% below its 52-week high.
- Pays a dividend yielding about 9.78% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Adlai Nortye Ltd..
Write a review
News about Adlai Nortye Ltd.
News & sentiment via Polygon.io
